Structure Therapeutics, Inc. Sponsored ADR (GPCR) just unveiled an announcement.
Structure Therapeutics Inc. has announced promising results from its Phase 2a obesity study, revealing a significant weight loss in participants using their novel oral GLP-1 receptor agonist, GSBR-1290. The study showed a mean weight reduction of 6.2%, with a third of participants losing 10% of their body weight. Additionally, the new tablet formulation of the drug proved effective and well-tolerated, with plans to begin a 36-week Phase 2b obesity study by the end of 2024. This news could signal a breakthrough in non-peptide, small molecule treatments for obesity, positioning Structure Therapeutics as a potential leader in the market.
Learn more about GPCR stock on TipRanks’ Stock Analysis page.
